Lifyorli Combined Therapy Significantly Improves Survival Rates in Ovarian Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CORT?
Source: Newsfilter
- Survival Rate Improvement: The ROSELLA trial demonstrated that the combination of Lifyorli and nab-paclitaxel resulted in a 35% reduction in the risk of death and extended median overall survival by 4.1 months, highlighting the significant efficacy of this regimen in treating platinum-resistant ovarian cancer.
- FDA Approval as New Standard: Lifyorli received FDA approval in March 2026 and has been included in the NCCN Guidelines as a preferred treatment for patients with platinum-resistant ovarian cancer, marking its critical role in clinical practice.
- Good Safety Profile: The safety of Lifyorli in combination with nab-paclitaxel was comparable to that of nab-paclitaxel alone, with no increase in adverse events, providing patients with a new therapeutic option.
- International Collaborative Research: The ROSELLA trial involved 381 patients across multiple countries, reflecting a global commitment to addressing the treatment of platinum-resistant ovarian cancer and advancing new therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 42.250
Low
50.00
Averages
91.00
High
121.00
Current: 42.250
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lifyorli Combined Therapy Significantly Improves Survival Rates in Ovarian Cancer
- Survival Rate Improvement: The ROSELLA trial demonstrated that the combination of Lifyorli and nab-paclitaxel resulted in a 35% reduction in the risk of death and extended median overall survival by 4.1 months, highlighting the significant efficacy of this regimen in treating platinum-resistant ovarian cancer.
- FDA Approval as New Standard: Lifyorli received FDA approval in March 2026 and has been included in the NCCN Guidelines as a preferred treatment for patients with platinum-resistant ovarian cancer, marking its critical role in clinical practice.
- Good Safety Profile: The safety of Lifyorli in combination with nab-paclitaxel was comparable to that of nab-paclitaxel alone, with no increase in adverse events, providing patients with a new therapeutic option.
- International Collaborative Research: The ROSELLA trial involved 381 patients across multiple countries, reflecting a global commitment to addressing the treatment of platinum-resistant ovarian cancer and advancing new therapies.
See More
Class Action Reminder for Corcept Therapeutics Shareholders
- Class Action Notification: Robbins LLP reminds all investors who purchased Corcept Therapeutics (NASDAQ: CORT) stock between October 31, 2024, and December 30, 2025, that a class action has been filed to protect shareholder rights and seek recovery of losses.
- FDA Concerns: The lawsuit alleges that Corcept misled investors regarding the viability of its new product candidate, relacorilant, claiming strong clinical trial support for its New Drug Application, while the FDA had raised concerns about the adequacy of clinical evidence, creating significant approval risks.
- Stock Price Plunge: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter regarding relacorilant, causing the stock price to plummet from $70.20 on December 30 to $34.80, a decline of 50.4%, severely impacting shareholder value.
- Shareholder Action Advice: Shareholders are encouraged to participate in the class action and may serve as lead plaintiffs representing other shareholders, with Robbins LLP offering contingency fee arrangements to ensure no upfront costs for pursuing recovery.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Critical Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that April 21, 2026, is the deadline to apply as lead plaintiff in the pending securities class action, urging investors to submit their losses before this date to participate in the lawsuit.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose warnings from the FDA regarding its lead drug candidate, relacorilant, which indicated that the clinical data lacked sufficient evidence of effectiveness, misleading investors about the company's prospects.
- Market Crash Impact: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter (CRL) from the FDA, the stock price plummeted from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting strong market disappointment.
- Information Gap Allegations: The complaint claims that Corcept's management was aware of the FDA's concerns regarding the data's validity yet continued to convey an optimistic approval outlook to investors, potentially exposing the company to legal liabilities due to misleading communications.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: From February 2024 to February 2026, PayPal is accused of overstating its ability to execute business plans, misleading investors about its prospects, with a lead plaintiff motion deadline of April 20, 2026.
- NuScale Risk Disclosure: NuScale Power is charged with failing to disclose significant risks associated with its nuclear projects from May to November 2025, requiring investors to act by April 20, 2026, indicating potential failure in its commercialization strategy.
- Corcept FDA Concerns: Corcept Therapeutics faces allegations of not disclosing FDA concerns regarding the effectiveness assessment of its hypertension treatment from October 2024 to December 2025, with a lead plaintiff motion deadline of April 21, 2026.
- Navan IPO Controversy: Navan is accused of failing to disclose a 39% increase in sales and marketing expenses during its October 2025 IPO, misleading investors about its business outlook, with a deadline for action by April 24, 2026.
See More
Zentalis Selects 400 mg Dose for Ovarian Cancer Treatment
- Dose Selection: Zentalis has chosen the 400 mg dose for its ovarian cancer treatment due to its significantly higher response rate compared to the 300 mg dose, enhancing its competitive edge in clinical trials.
- Trial Progress: The company expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026, paving the way for potential regulatory approval and further business development.
- Stock Surge: Following a bullish analyst call, Zentalis's shares soared over 40% on Friday, reaching their highest level since June 2024, reflecting market confidence in the drug's success.
- Analyst Rating Upgrade: Guggenheim raised Zentalis's price target from $6 to $10, indicating increased confidence in the drug's chances of success in platinum-resistant ovarian cancer, suggesting a potential 56% upside from the current stock price.
See More
Corcept Therapeutics Shareholder Notice Issued
- Shareholder Lawsuit Notice: The Gross Law Firm has issued a notice to shareholders of Corcept Therapeutics (NASDAQ: CORT), encouraging those who purchased shares during the class period from October 31, 2024, to December 30, 2025, to contact the firm regarding potential lead plaintiff appointment, indicating legal risks for the company.
- FDA Concerns Raised: According to the filed complaint, the FDA expressed concerns about the adequacy of Corcept's program assessing the effectiveness of relacorilant in treating hypertension in patients with hypercortisolism, highlighting significant issues with the design of the GRACE study that could impact the NDA review process.
- Allegations of False Statements: The defendants are accused of making materially false or misleading statements regarding their interactions with the FDA, leading to unrealistic expectations among investors about the approval of the relacorilant NDA, which may have resulted in shareholder losses.
- Steps for Participation: Shareholders must register by April 21, 2026, to participate in the class action lawsuit, and upon registration, they will receive status updates throughout the lifecycle of the case, reflecting the company's commitment to shareholder rights.
See More
Lifyorli Combined Therapy Significantly Improves Survival Rates in Ovarian Cancer
- Survival Rate Improvement: The ROSELLA trial demonstrated that the combination of Lifyorli and nab-paclitaxel resulted in a 35% reduction in the risk of death and extended median overall survival by 4.1 months, highlighting the significant efficacy of this regimen in treating platinum-resistant ovarian cancer.
- FDA Approval as New Standard: Lifyorli received FDA approval in March 2026 and has been included in the NCCN Guidelines as a preferred treatment for patients with platinum-resistant ovarian cancer, marking its critical role in clinical practice.
- Good Safety Profile: The safety of Lifyorli in combination with nab-paclitaxel was comparable to that of nab-paclitaxel alone, with no increase in adverse events, providing patients with a new therapeutic option.
- International Collaborative Research: The ROSELLA trial involved 381 patients across multiple countries, reflecting a global commitment to addressing the treatment of platinum-resistant ovarian cancer and advancing new therapies.
See More
Class Action Reminder for Corcept Therapeutics Shareholders
- Class Action Notification: Robbins LLP reminds all investors who purchased Corcept Therapeutics (NASDAQ: CORT) stock between October 31, 2024, and December 30, 2025, that a class action has been filed to protect shareholder rights and seek recovery of losses.
- FDA Concerns: The lawsuit alleges that Corcept misled investors regarding the viability of its new product candidate, relacorilant, claiming strong clinical trial support for its New Drug Application, while the FDA had raised concerns about the adequacy of clinical evidence, creating significant approval risks.
- Stock Price Plunge: On December 31, 2025, Corcept revealed that the FDA issued a Complete Response Letter regarding relacorilant, causing the stock price to plummet from $70.20 on December 30 to $34.80, a decline of 50.4%, severely impacting shareholder value.
- Shareholder Action Advice: Shareholders are encouraged to participate in the class action and may serve as lead plaintiffs representing other shareholders, with Robbins LLP offering contingency fee arrangements to ensure no upfront costs for pursuing recovery.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Critical Deadline: Hagens Berman law firm reminds shareholders of Corcept Therapeutics that April 21, 2026, is the deadline to apply as lead plaintiff in the pending securities class action, urging investors to submit their losses before this date to participate in the lawsuit.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose warnings from the FDA regarding its lead drug candidate, relacorilant, which indicated that the clinical data lacked sufficient evidence of effectiveness, misleading investors about the company's prospects.
- Market Crash Impact: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter (CRL) from the FDA, the stock price plummeted from $70.20 on December 30, 2025, to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, reflecting strong market disappointment.
- Information Gap Allegations: The complaint claims that Corcept's management was aware of the FDA's concerns regarding the data's validity yet continued to convey an optimistic approval outlook to investors, potentially exposing the company to legal liabilities due to misleading communications.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: From February 2024 to February 2026, PayPal is accused of overstating its ability to execute business plans, misleading investors about its prospects, with a lead plaintiff motion deadline of April 20, 2026.
- NuScale Risk Disclosure: NuScale Power is charged with failing to disclose significant risks associated with its nuclear projects from May to November 2025, requiring investors to act by April 20, 2026, indicating potential failure in its commercialization strategy.
- Corcept FDA Concerns: Corcept Therapeutics faces allegations of not disclosing FDA concerns regarding the effectiveness assessment of its hypertension treatment from October 2024 to December 2025, with a lead plaintiff motion deadline of April 21, 2026.
- Navan IPO Controversy: Navan is accused of failing to disclose a 39% increase in sales and marketing expenses during its October 2025 IPO, misleading investors about its business outlook, with a deadline for action by April 24, 2026.
See More
Zentalis Selects 400 mg Dose for Ovarian Cancer Treatment
- Dose Selection: Zentalis has chosen the 400 mg dose for its ovarian cancer treatment due to its significantly higher response rate compared to the 300 mg dose, enhancing its competitive edge in clinical trials.
- Trial Progress: The company expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026, paving the way for potential regulatory approval and further business development.
- Stock Surge: Following a bullish analyst call, Zentalis's shares soared over 40% on Friday, reaching their highest level since June 2024, reflecting market confidence in the drug's success.
- Analyst Rating Upgrade: Guggenheim raised Zentalis's price target from $6 to $10, indicating increased confidence in the drug's chances of success in platinum-resistant ovarian cancer, suggesting a potential 56% upside from the current stock price.
See More
Corcept Therapeutics Shareholder Notice Issued
- Shareholder Lawsuit Notice: The Gross Law Firm has issued a notice to shareholders of Corcept Therapeutics (NASDAQ: CORT), encouraging those who purchased shares during the class period from October 31, 2024, to December 30, 2025, to contact the firm regarding potential lead plaintiff appointment, indicating legal risks for the company.
- FDA Concerns Raised: According to the filed complaint, the FDA expressed concerns about the adequacy of Corcept's program assessing the effectiveness of relacorilant in treating hypertension in patients with hypercortisolism, highlighting significant issues with the design of the GRACE study that could impact the NDA review process.
- Allegations of False Statements: The defendants are accused of making materially false or misleading statements regarding their interactions with the FDA, leading to unrealistic expectations among investors about the approval of the relacorilant NDA, which may have resulted in shareholder losses.
- Steps for Participation: Shareholders must register by April 21, 2026, to participate in the class action lawsuit, and upon registration, they will receive status updates throughout the lifecycle of the case, reflecting the company's commitment to shareholder rights.
See More
